Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2023-06-28 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Imugene PD1-Vaxx patent extended to 2040 2 pages 129.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement regarding the extension of a patent for Imugene's PD1-Vaxx technology. It provides details about the patent grant, its expiration date, and the significance of the patent for the company's product development. There are no financial statements, quarterly or annual results, or detailed management discussions. The document is relatively short (3,713 characters) and serves as a news release about a patent grant rather than a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is a general regulatory announcement about intellectual property, which falls under Regulatory Filings (RNS).
2023-06-28 English
Initial Director's Interest Notice 2 pages 143.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the appointment of a director and their relevant interests in securities, including sections on securities held and contracts related to the director. The content is focused on reporting personal share transactions or interests of a company director. There is no financial data, earnings information, or report publication mentioned. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is short and specific to director interests, confirming it is not a broader report or announcement.
2023-06-22 English
Imugene Appoints Kim Drapkin as Non-Executive Director 3 pages 139.9KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement about the appointment of a new Non-Executive Director and the resignation of an existing board member. It focuses on changes in the company's board of directors and provides biographical details of the new appointee and a statement of thanks to the departing director. There is no financial data, no report attached or referenced, and no mention of voting results or other meeting materials. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-06-20 English
Imugene Advances VAXINIA MAST Trial to Next IV Cohorts 3 pages 176.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited about the advancement of their Phase 1 MAST clinical trial to the next cohort stages. It discusses clinical trial progress, study details, and company information. There are no financial statements, earnings data, or regulatory filings related to financial performance. The content is a corporate announcement about clinical trial progress, not a financial report or management discussion. It is not a report publication announcement since it contains substantive information about the trial advancement. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and company updates that do not fit into other specific financial or governance categories.
2023-06-08 English
Imugene doses first combination patient in PD1-Vaxx trial 3 pages 163.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited about dosing the first patient in a clinical trial combining PD1-Vaxx and an immune checkpoint inhibitor for lung cancer. It discusses the clinical trial design, objectives, and collaboration details. There are no financial statements, regulatory certifications, or detailed financial data. The document is a news release announcing a clinical trial milestone, which fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like Annual Report, Earnings Release, or Investor Presentation. The document length is 6208 characters, which is sufficient for a detailed announcement but does not contain financial or management report data. Therefore, the best classification is Regulatory Filings (RNS).
2023-05-31 English
FDA clears Imugene IND for onCARlytics first-in-class study 5 pages 310.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 19 May 2023 from Imugene Limited regarding FDA clearance of an Investigational New Drug (IND) application to commence a Phase 1 clinical study for their oncolytic virotherapy candidate onCARlytics. The content focuses on the clinical trial initiation, scientific background, and company information. It is a regulatory announcement about a clinical trial clearance and does not contain financial data, earnings, management changes, or detailed financial reports. It is not a report publication announcement since it is a substantive announcement about a regulatory milestone. The document fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into other specific categories such as earnings release, capital update, or management information.
2023-05-18 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.